Carcinoma mammario HER2+ Trattamento delle pazienti con metastasi cerebrali
|
|
|
- Anastasia Gibson
- 5 years ago
- Views:
Transcription
1 Carcinoma mammario HER2+ Trattamento delle pazienti con metastasi cerebrali Stefania Gori Presidente Nazionale AIOM U.O.C. Oncologia Medica Cancer Care Center Sacro Cuore-Don Calabria Negrar- Verona Associazione Italiana Oncologia Medica
2 HER2+MBC pts treated with trastuzumab-based therapy No. of pts CNS metastases incidence CNS as only site of PD Clayton AJ, Brit J Cancer 2004 Bendell JC, Cancer 2003 Heinrich B, ASCO 2003 Brufsky AM, ASCO 2003 Shmueli E, E J Cancer 2004 Stemmler HJ, Breast 2006 Montagna E, Cancer Chem Pharm 2009 Gori S, Oncologist % 78% % 71% 51 43% 79% 38 50% nr 41 24% 31% % 48% 78 46% nr % 62%
3 SURVIVAL from CNS metastases development in HER2+MBC and trastuzumab-based therapy No. of pts with CNS disease Median OS Bendell mo 21% Clayton mo 43% Kirsch mo 77% Eichler mo 80% Nam mo 60% Metro NR* 50% Gori mo 39.5% Pts treated with T after CNS *NR= not reached at f.up of 17 mo from the diagnosis of CNS metastases
4 Survival from the diagnosis of CNS metastases by treatment Gori S et al, Oncologist 2007; 12:1469 Dawood S, Ann Oncol 2008 Nam B-H et al, Breast Cancer Res 2008
5 Brain metastases in HER2+ breast cancer Impact of the response to systemic therapy at extracranial sites on survival Overall survival Control 29.8 months Progression 6.7 months Gori S, Oncologist 2007
6 Brain metastases in HER2+ breast cancer Goals of treatment Neurologic symptoms control Quality of Life Survival
7 Brain metastases in HER2+ breast cancer Causes of death PRE-Trastuzumab era POST-Trastuzumab era p Park YH, BJC 2009 Progression in the brain 46% 60% ns Progression in extra-cns sites 37% 12% Unknown 17% 28% - Bendell JC, Cancer 2003 Progression in the brain - 52% - Progression in extra-cns +/- CNS sites - 48% -
8 Impact of systemic therapy on survival by subtype Median survival from brain metastases after WBRT No No systemic therapy CT/HT CT/HT and trastuzumab p TN 57 3 mo 4 mo HER2+ HR mo 8 mo 10 mo HER2+ HR mo 8 mo 13 mo Luminal 39 3 mo 14 mo Niwinska A, Ann Oncol 2010;21:
9 Ramakrishna N et al, JCO 2014;32:
10 Recommendations on management for HER2+BC and brain metastases : ASCO 2014
11 Systemic therapy in brain metastases from HER2+ BC
12 HER2+ metastatic breast cancer T-MD1* Trastuzumab* Pertuzumab* Lapatinib* Neratinib *AIFA Approved Neratinib is a small molecule, irreversible pan-erbb receptor inhibitor that blocks signalling through the erbb-2 pathway by acting intracellularly as a TK-inhibitor
13 HER2 STATUS concordance between primitive tumor and brain metastases PRIMARY T (= n) CNS METASTASES (= n) CONCORDANCE 13 HER HER % FUCHS I.B. JCO 2002; 20: HER2-15 HER2-1 HER2 + Global Concordance 97% LEAR-KAUL K.C. ARCH. PATHOL. LAB. MED. 2003; 127: * 10* 100% IBRAHIM N.K. ASCO 2006; 24 (suppl. 18) # % TOMASEVIC Z. ASCO 2010 # HER2 + 4 HER2 + 8 HER2-6 HER2-2 HER2 + (25% HER2- HER2 +) NR * FISH amplified
14 CNS blood brain barrier BBB=blood brain barrier; CSF=cerebrospinal fluid 1. Azim HA & Azim HA. Future Oncol 2012;8: Stemmler HJ & Heinemann V. The Oncologist 2008;13: Taskar KS et al. Pharm Res 2012; 29: Gril, et al. JNCI 2008; 100: The blood brain barrier (BBB) is permeable to substances with a diameter of < 20 nm 1 Trastuzumab (~145 kda) has limited ability to cross the BBB Lapatinib (~1 kda) has a higher potential to cross the BBB Studies show: Trastuzumab levels in CSF fold lower than in serum 2 In animals, lapatinib levels 7-9 fold higher in brain tumour tissue compared to healthy brain tissue 3 In animals, lapatinib inhibits formation of large brain metastases by HER2+ brainseeking breast cancer calls 4 Whole brain radiotherapy may increase the permeability of the blood brain barrier
15
16 Systemic therapy in brain metastases from HER2+ BC: LAPATINIB
17 Lapatinib+Capecitabine (all pts pretreated with CT) STUDY N Prior cranial RT Prior trastuzumab Prior Cape Response criteria CNS ORR TTP- PFS OS RETROSPECTIVE STUDIES Boccardo F ASCO 2008 #1094 Capri G 138 NR YES YES: 42% Investigatorassessed 18% 2.8 mo (median time on study) NR Ann Oncol 2010 Sutherland S BJC 2010;102: YES (94%) YES YES: 35% RECIST 21% 5.1 mo NR Huang C ASCO 2010 #1111 Metro G Ann Oncol YES (100%) YES NO RECIST 34% 8.4 mo NR 22 YES (87%) YES NO WHO 32% 5.1 mo 27.9 mo PHASE II PROSPECTIVE STUDIES Lin NU CCR 2009;15: Lin NU J Neurooncol * YES (100%) YES NO Composita ( 50% vol ) 13 YES (100%) YES NO Composita ( 50% vol ) 20% 3.6 mo NR 38% NR NR *extension phase: in 50 pts with progression only in CNS
18 Lapatinib+Capecitabine (all pts pretreated with CT) STUDY N Prior cranial RT Prior trastuzumab Prior Cape Response criteria CNS ORR TTP- PFS OS RETROSPECTIVE STUDIES Boccardo F ASCO 2008 #1094 Capri G 138 NR YES YES: 42% Investigatorassessed 18% 2.8 mo (median time on study) NR Ann Oncol 2010 Sutherland S BJC 2010;102: YES (94%) YES YES: 35% RECIST 21% 5.1 mo NR Huang C ASCO 2010 #1111 Metro G Ann Oncol YES (100%) YES NO RECIST 34% 8.4 mo NR 22 YES (87%) YES NO WHO 32% 5.1 mo 27.9 mo PHASE II PROSPECTIVE STUDIES Lin NU CCR 2009;15: Lin NU J Neurooncol * YES (100%) YES NO Composita ( 50% vol ) 13 YES (100%) YES NO Composita ( 50% vol ) 20% 3.6 mo NR 38% NR NR Bachelot T Lancet Oncol 2014; 14: NO YES (93%) NO Composita ( 50% vol ) 67% 5.5 mo 91% alive at 6 mo
19 LANDSCAPE: a FNCLCC phase II study with lapatinib+capecitabine in patients with brain metastases from HER2+ MBC before WBRT Objective : Evaluate the clinical interest of L+C combination for BM in HER2+ MBC patients not previously treated with WBRT Treatment of patients with BM at their onset may be a way: To start at once an active systemic treatment To delay WBRT and associated toxicities Enrolled 45 pts: HER2+ MBC Newly diagnosed brain metastases, at least 1 cm in diameter (T1 MRI) Not candidate for brain surgery Any previous treatment except WBRT, lapatinib or capecitabine ECOG PS status 0-2 Treatment: L: 1,250 mg/d, PO, continuous+ C: 2,000 mg/m²/d, PO, d1 14 q3weeks Bachelot T et al, Lancet Oncol 2013; 14:64-71
20 Primary Endpoint: CNS volumetric reduction CNS objective response =65.9% COMPOSITE CRITERIA Primary endpoint: Centrally assessed CNS objective response (CNS-OR) defined as a 50% volumetric reduction of CNS lesions in the absence of: increasing steroid use progressive neurologic symptoms progressive extra-cns disease (RECIST) Bachelot T et al, Lancet Oncol 2013; 14:64-71
21 Bachelot T et al, Lancet Oncol 2013; 14:64-71 Median time to progression: 5.5 mos First progression CNS: n = 32/41 (78%); median time to CNS progression was 5.5 mos First progression extra-cns: n = 2/41 (5%) ;Progression both CNS/extra-CNS: n = 5/41 (12%) Median time to WBRT is 8.3 months
22 Systemic therapy in brain metastases from HER2+ BC: NERATINIB
23 Neratinib Presented By Rachel Freedman at 2017 ASCO Annual Meeting
24 TBCRC 022 Study Cohorts Presented By Rachel Freedman at 2017 ASCO Annual Meeting
25 Slide 8 Presented By Rachel Freedman at 2017 ASCO Annual Meeting
26 Slide 9 Presented By Rachel Freedman at 2017 ASCO Annual Meeting
27 Slide 10 Presented By Rachel Freedman at 2017 ASCO Annual Meeting
28 Requirements for Partial Response Presented By Rachel Freedman at 2017 ASCO Annual Meeting
29 MRI standardized guidelines Efficacy assessment Central and blind volumetric evaluation of CNS lesions All target lesions contoured across all slices, T1 SE axial 5mm Gado. The software calculated the tumor volume of every target lesion: Tumor volume = (outlined surfaces x slice thickness) * *Lin NU et al. JCO 2008; 26: ; Lin NU et al. Clin Cancer Res 2009; 15:
30 Requirements for Partial Response Presented By Rachel Freedman at 2017 ASCO Annual Meeting
31 Slide 16 CNS RESPONSE EVALUATED BY COMPOSITE CRITERIA Presented By Rachel Freedman at 2017 ASCO Annual Meeting
32 Time to CNS Progression Presented By Rachel Freedman at 2017 ASCO Annual Meeting
33 Slide 20 Presented By Rachel Freedman at 2017 ASCO Annual Meeting
34 Slide 25 Presented By Rachel Freedman at 2017 ASCO Annual Meeting
35 HER2+ BC and brain metastases: QUESTIONS What s changing?
36 Linee Guida AIOM 2017 Figura 14 CARCINOMA MAMMARIO METASTATICO HER2-positivo Terapia medica in base alle caratteristiche patologiche e cliniche (I) ER+ Post-menopausa: qualora non si ritenga indicata chemioterapia 1 Pre/post-menopausa: malattia aggressiva 1 AI + Trastuzumab o Lapatinib 2 PD 3 HER2+ ER- Docetaxel+ Trastuzumab+ Pertuzumab 4 QUESITO 14 Trastuzumab + CT TDM-1 5,1 Lapatinib+Capecitabina Trastuzumab+CT 6 Lapatinib+ Capecitabina Trastuzumab+CT 6 TDM-1 5 I A linea II A linea III A linea* Nota 1- Vedere paragrafo Nota 2- Il trattamento ormonale con AI+ un farmaco anti HER2 è un opzione alternativa alla chemioterapia, ma non esistono studi di confronto diretto Nota 3- nel caso in cui la paziente abbia ricevuto la sola ormonoterapia, il trattamento alla progressione dovrebbe essere prevedere le opzioni contemplate in I A linea. Nel caso in cui la paziente abbia ricevuto ormonoterapia in combinazione con un farmaco anti HER2, il trattamento alla progressione dovrebbe essere TDM-1 se sono soddisfatti i criteri di eleggibilità (precedente trattamento con taxano e trastuzumab); in caso contrario, la paziente dovrebbe ricevere trastuzumab e chemioterapia o lapatinib e capecitabina a seconda del tipo di anti HER2 utilizzato in associazione con il trattamento ormonale. Nota 4-Indicazioni AIFA: Pertuzumab è indicato in associazione a Trastuzumab e docetaxel in pazienti adulte con carcinoma mammario HER2-positivo non operabile o metastatico o localmente recidivato non trattate in precedenza con terapia anti-her2 o chemioterapia per la malattia metastatica (vedi testo per criteri di eligibilità e per caratteristiche delle pts incluse). Nella scheda AIFA è possibile l utilizzo di paclitaxel in caso di controindicazioni assolute al docetaxel (vedi testo). Nota 5 Indicazioni AIFA: Il Trastuzumab emtasine, in monoterapia, è indicato per il trattamento di pazienti adulti affetti da tumore mammario HER2-positivo, inoperabile, localmente avanzato o metastatico, sottoposti in precedenza a trattamento con trastuzumab e un taxano, somministrati separatamente o in associazione. Le pazienti devono: essere state sottoposte in precedenza a terapia per la malattia localmente avanzata o metastatica, oppure aver sviluppato recidiva di malattia nel corso di o entro 6 mesi dal completamento della terapia adiuvante. Nota 6-Chemioterapico non utilizzato in precedenza. *Linee terapeutiche superiori alla III A sono possibili sulla base delle condizioni cliniche della paziente e sulla presenza di opzioni ragionevoli considerando il rapporto tossicità/efficacia
37
38 Pertuzumab+Trastuzumab+Docetaxel delays the onset of CNS disease compared with placebo+t+docetaxel
39
40 EMILIA Study Design EMILIA: T-DM1 after disease progression HER2+ (central) LABC or MBC (N=980) Prior taxane and trastuzumab 1:1 T-DM1 3.6 mg/kg q3w IV PD Progression on metastatic tx or within 6 mos of adjuvant tx Capecitabine 1000 mg/m 2 orally bid, days 1 14, q3w + Lapatinib 1250 mg/day orally qd PD Primary endpoints: PFS by independent review, OS, and safety Outcome T-DM1 Lap +Cap HR (95%CI); p value Median PFS 9.6 mo 6.4 mo 0.65 ( ); p <.001 Median OS 30.9 mo 25.1 mo 0.68 ( ); p <.001 Rate of grade 3-4 AEs lower with T-DM1 vs Lapatinib+Capecitabine (41% vs 57%) Verma S, NEJM 2012; 367:
41 EMILIA: SNC metastases Retrospective analysis Krop J et al. SABCC 2013
42 Krop J et al. SABCC 2013
43 Krop J et al. SABCC 2013
44 Krop J et al. SABCC 2013
45 ECCO 2013 #LBA15 (Phase 3) N=602
46 TH3RESA trial- ECCO 2013 #LBA15
47 TH3RESA trial- ECCO 2013 #LBA15
48 HER2+ BC and brain metastases: QUESTIONS How to integrate surgery, SRS, WBRT, systemic therapy? What is the appropriate sequencing? What systemic therapy?
49 Local and systemic therapy in brain metastases from HER2+ BC: Extracranial disease and brain lesions Multiple brain lesions Local treatment WBRT Systemic therapy Systemic therapy Systemic therapy WBRT The choice of systemic therapy must be tailored on the following factors: Performance Status and previous agents received
50 Brain metastases in HER2+ breast cancer Causes of death PRE-Trastuzumab era POST-Trastuzumab era p Park YH, BJC 2009 Progression in the brain 46% 60% ns Progression in extra-cns sites 37% 12% Unknown 17% 28% - Bendell JC, Cancer 2003 Progression in the brain - 52% - Progression in extra-cns +/- CNS sites - 48% -
51 Local and systemic therapy in brain metastases from HER2+ BC: TRASTUZUMAB WITH CONCURRENT WBRT radiologic ORR (WHO)= 74% at 6 wks (23/31)* concurrent? low trastuzumab-related toxicity Chargary C, Int J Radiat Oncol Biol Phys 2010 LAPATINIB WITH CONCURRENT WBRT volumetric ORR=70% at 2 mo presently, no utilisation in clinical practice Lin NU, ASCO 2010 #1154 *Concurrent CT=42%; Time to Brain PD=10.5 mo
52 HER2/ TKIs were associated with a decreased rate of distant and local failure 12-month cumulative incidences local intracranial failure D=9,4 mo D=8,2 mo Only SRS 15.1% (95% CI, 11.1%- 19.0%) SRS +concurrent TKIs 5.7% (95% CI, 2.1%- 9.4%) Only HER2-Ab 18.4% (95% CI, 10.9%- 26.0%) SRS+ concurrent HER2-Ab 10.2% (95% CI, 7.1%- 13.3%) Miller, J. A. et al, Cancer 2017; 123,
53 Systemic therapy in brain metastases from HER2+ BC: what? Newly diagnosed brain metastases and no PD at extracranial sites NOT switch systemic therapy Newly diagnosed brain metastases and PD at extracranial sites HER2 targeted therapy according to the algoritms for treatment of HER2-MBC
54 Linee Guida AIOM 2017 Figura 14 CARCINOMA MAMMARIO METASTATICO HER2-positivo Terapia medica in base alle caratteristiche patologiche e cliniche (I) ER+ Post-menopausa: qualora non si ritenga indicata chemioterapia 1 Pre/post-menopausa: malattia aggressiva 1 AI + Trastuzumab o Lapatinib 2 PD 3 HER2+ ER- Docetaxel+ Trastuzumab+ Pertuzumab 4 QUESITO 14 Trastuzumab + CT TDM-1 5,1 Lapatinib+Capecitabina Trastuzumab+CT 6 Lapatinib+ Capecitabina Trastuzumab+CT 6 TDM-1 5 I A linea II A linea III A linea* Nota 1- Vedere paragrafo Nota 2- Il trattamento ormonale con AI+ un farmaco anti HER2 è un opzione alternativa alla chemioterapia, ma non esistono studi di confronto diretto Nota 3- nel caso in cui la paziente abbia ricevuto la sola ormonoterapia, il trattamento alla progressione dovrebbe essere prevedere le opzioni contemplate in I A linea. Nel caso in cui la paziente abbia ricevuto ormonoterapia in combinazione con un farmaco anti HER2, il trattamento alla progressione dovrebbe essere TDM-1 se sono soddisfatti i criteri di eleggibilità (precedente trattamento con taxano e trastuzumab); in caso contrario, la paziente dovrebbe ricevere trastuzumab e chemioterapia o lapatinib e capecitabina a seconda del tipo di anti HER2 utilizzato in associazione con il trattamento ormonale. Nota 4-Indicazioni AIFA: Pertuzumab è indicato in associazione a Trastuzumab e docetaxel in pazienti adulte con carcinoma mammario HER2-positivo non operabile o metastatico o localmente recidivato non trattate in precedenza con terapia anti-her2 o chemioterapia per la malattia metastatica (vedi testo per criteri di eligibilità e per caratteristiche delle pts incluse). Nella scheda AIFA è possibile l utilizzo di paclitaxel in caso di controindicazioni assolute al docetaxel (vedi testo). Nota 5 Indicazioni AIFA: Il Trastuzumab emtasine, in monoterapia, è indicato per il trattamento di pazienti adulti affetti da tumore mammario HER2-positivo, inoperabile, localmente avanzato o metastatico, sottoposti in precedenza a trattamento con trastuzumab e un taxano, somministrati separatamente o in associazione. Le pazienti devono: essere state sottoposte in precedenza a terapia per la malattia localmente avanzata o metastatica, oppure aver sviluppato recidiva di malattia nel corso di o entro 6 mesi dal completamento della terapia adiuvante. Nota 6-Chemioterapico non utilizzato in precedenza. *Linee terapeutiche superiori alla III A sono possibili sulla base delle condizioni cliniche della paziente e sulla presenza di opzioni ragionevoli considerando il rapporto tossicità/efficacia
55 Systemic therapy in brain metastases from HER2+ BC: what? Newly diagnosed brain metastases and no PD at extracranial sites NOT switch systemic therapy Newly diagnosed brain metastases and PD at extracranial sites HER2 targeted therapy according to the algoritms for treatment of HER2-MBC Newly diagnosed, asymptomatic and low volume brain metastases, no treated with RT Lapatinib + capecitabine (?) phase II trial 1 1.Bachelot T, Lancet Oncol 2013
56 Systemic therapy in brain metastases from HER2+ BC: what? Newly diagnosed brain metastases and no PD at extracranial sites NOT switch systemic therapy Newly diagnosed brain metastases and PD at extracranial sites HER2 targeted therapy according to the algoritms for treatment of HER2-MBC Newly diagnosed, asymptomatic and low volume brain metastases, no treated with RT Lapatinib + capecitabine (?) phase II trial 1 1.Bachelot T, Lancet Oncol 2013
57 Linee Guida AIOM 2017 Figura 14 CARCINOMA MAMMARIO METASTATICO HER2-positivo Terapia medica in base alle caratteristiche patologiche e cliniche (I) ER+ Post-menopausa: qualora non si ritenga indicata chemioterapia 1 Pre/post-menopausa: malattia aggressiva 1 AI + Trastuzumab o Lapatinib 2 PD 3 HER2+ ER- Docetaxel+ Trastuzumab+ Pertuzumab 4 QUESITO 14 Trastuzumab + CT TDM-1 5,1 Lapatinib+Capecitabina Trastuzumab+CT 6 Lapatinib+ Capecitabina Trastuzumab+CT 6 TDM-1 5 I A linea II A linea III A linea* Nota 1- Vedere paragrafo Nota 2- Il trattamento ormonale con AI+ un farmaco anti HER2 è un opzione alternativa alla chemioterapia, ma non esistono studi di confronto diretto Nota 3- nel caso in cui la paziente abbia ricevuto la sola ormonoterapia, il trattamento alla progressione dovrebbe essere prevedere le opzioni contemplate in I A linea. Nel caso in cui la paziente abbia ricevuto ormonoterapia in combinazione con un farmaco anti HER2, il trattamento alla progressione dovrebbe essere TDM-1 se sono soddisfatti i criteri di eleggibilità (precedente trattamento con taxano e trastuzumab); in caso contrario, la paziente dovrebbe ricevere trastuzumab e chemioterapia o lapatinib e capecitabina a seconda del tipo di anti HER2 utilizzato in associazione con il trattamento ormonale. Nota 4-Indicazioni AIFA: Pertuzumab è indicato in associazione a Trastuzumab e docetaxel in pazienti adulte con carcinoma mammario HER2-positivo non operabile o metastatico o localmente recidivato non trattate in precedenza con terapia anti-her2 o chemioterapia per la malattia metastatica (vedi testo per criteri di eligibilità e per caratteristiche delle pts incluse). Nella scheda AIFA è possibile l utilizzo di paclitaxel in caso di controindicazioni assolute al docetaxel (vedi testo). Nota 5 Indicazioni AIFA: Il Trastuzumab emtasine, in monoterapia, è indicato per il trattamento di pazienti adulti affetti da tumore mammario HER2-positivo, inoperabile, localmente avanzato o metastatico, sottoposti in precedenza a trattamento con trastuzumab e un taxano, somministrati separatamente o in associazione. Le pazienti devono: essere state sottoposte in precedenza a terapia per la malattia localmente avanzata o metastatica, oppure aver sviluppato recidiva di malattia nel corso di o entro 6 mesi dal completamento della terapia adiuvante. Nota 6-Chemioterapico non utilizzato in precedenza. *Linee terapeutiche superiori alla III A sono possibili sulla base delle condizioni cliniche della paziente e sulla presenza di opzioni ragionevoli considerando il rapporto tossicità/efficacia
58 Trastuzumab Lapatinib Scaltriti M, Oncogene 2009
59
60 PFS=12 mos This longer PFS to TDM1 III line could be associated with PRIOR Lapatinib PFS=5 mos Fabi A. et al, Oncotarget 2017
61 HER2+ BC and brain metastases: QUESTIONS Screening of brain metastases
62 Recommendations on management for HER2+BC and brain metastases : ASCO 2014 Ramakrishna N et al, JCO 2014;32:
63
Evolving Paradigms in HER2+ MBC: Strategies for Individualizing Therapy with Available Agents
Evolving Paradigms in HER2+ MBC: Strategies for Individualizing Therapy with Available Agents Kimberly L. Blackwell MD Professor Department of Medicine and Radiation Oncology Duke University Medical Center
Cerebel trial Any impact on the clinical practice? Antonio Frassoldati Oncologia Clinica - Ferrara
Cerebel trial Any impact on the clinical practice? Antonio Frassoldati Oncologia Clinica - Ferrara CNS metastases in HER2+ BC The proportion of patients with HER2+ advanced breast cancer who have CNS metastases
PROGNOSTICO DE PACIENTES COM CA DE MAMA METASTATICO HER2+: PODEMOS FAZER MAIS? TDM-1 AND BEYOND!
II Simpósio Internacional de Câncer de Mama para o Oncologista Clínico PROGNOSTICO DE PACIENTES COM CA DE MAMA METASTATICO HER2+: PODEMOS FAZER MAIS? TDM-1 AND BEYOND! INGRID A. MAYER, MD, MSCI Assistant
Update on the Management of HER2+ Breast Cancer. Christian Jackisch, MD, PhD Sana Klinikum Offenbach Offenbach, Germany
Update on the Management of HER2+ Breast Cancer Christian Jackisch, MD, PhD Sana Klinikum Offenbach Offenbach, Germany Outline Treatment strategies for HER2-positive metastatic breast cancer since First
Highlitghs in MBC First and second line endocrine treatments. Antonio Frassoldati Oncologia Clinica Ferrara
Highlitghs in MBC First and second line endocrine treatments Antonio Frassoldati Oncologia Clinica Ferrara Which clinical scenario have to face First line therapy with today? Untreated metastatic breast
Her 2 Positive Advanced Breast Cancer: From Evidence to Practice
Her 2 Positive Advanced Breast Cancer: From Evidence to Practice Sunil Verma MD, FRCP(C) Medical Director, Tom Baker Cancer Center Professor and Head, Department of Oncology Cumming School of Medicine,
Addressing Brain Metastases in HER2-Positive Breast Cancer
Addressing Brain Metastases in HER2-Positive Breast Cancer Carlos Barrios, MD PUCRS School of Medicine Instituto do Câncer Hospital Mãe de Deus Latin American Clinical Oncology Group (LACOG) Porto Alegre,
Update in the treatment of Her2- overexpressing breast cancers. Fabrice ANDRE Institut Gustave Roussy Villejuif, France
Update in the treatment of Her2- overexpressing breast cancers Fabrice ANDRE Institut Gustave Roussy Villejuif, France Questions Should tumors
Sessione 4: La malattia metastatica. La malattia HER2-positiva: strategia terapeutica nella pratica clinica e il futuro G.
Sessione 4: La malattia metastatica La malattia HER2-positiva: strategia terapeutica nella pratica clinica e il futuro G. RICCIARDI UOC Oncologia Medica, A.O. Papardo, Messina Dir. Prof. V. Adamo giusyricciardi81@hotmail.it
Expanding Therapeutic Strategies for HER2-Positive Metastatic Breast Cancer
Expanding Therapeutic Strategies for HER2-Positive Metastatic Breast Cancer Sara A. Hurvitz, MD, FACP Associate Professor of Medicine University of California Los Angeles Los Angeles, California Trastuzumab
Overcoming resistance to endocrine or HER2-directed therapy
Overcoming resistance to endocrine or HER2-directed therapy Jane Lowe Meisel, MD Assistant Professor of Hematology and Medical Oncology Winship Cancer Institute at Emory University 1 Background While most
LA CHEMIOTERAPIA DI I LINEA
DECIDERE LA CHEMIOTERAPIA ADIUVANTE E DELLA MALATTIA METASTATICA LA CHEMIOTERAPIA DI I LINEA Michele Reni Department of Medical Oncology IRCCS Ospedale San Raffaele Milan, Italy 1930 1940 1950 1960 1970
HER2-Targeted Rx. An Historical Perspective
HER2-Targeted Rx An Historical Perspective Trastuzumab: Front Line Rx for MBC Median 20.3 v. 25.1 mo P = 0.046 HR 0.8 65% of control patients crossed over Slamon D, et al. N Engl J Med, 2001; 344:783 Trastuzumab:Front-line
Breast : ASCO Abstracts for Review
Breast : ASCO 2011 Susana Campos, MD, MPH Dana Farber Cancer Institute Abstracts for Review Prevention Neoadjuvant Metastatic Brain mets LBA 504: Exemestane for primary prevention of breast cancer in postmenopausal
Her 2 Positive Metastatic Breast Cancer
Her 2 Positive Metastatic Breast Cancer Alison Jones November 2013 Mrs Hermione Positive (then and now!) Diagnosed 2007 T2 N1 Mo ER ve; Her2 ve Mastectomy ANC; FEC/T Herceptin (12months) August 2010metastatic
Opzioni terapeutiche nel paziente ALK-traslocato
Opzioni terapeutiche nel paziente ALK-traslocato Giulio Metro S.C. Oncologia Medica Ospedale Santa Maria della Misericordia, Azienda Ospedaliera di Perugia Carcinoma del polmone non microcitoma: quali
New Drug Development in HER2+ Breast Cancer
New Drug Development in HER2+ Breast Cancer Philippe Aftimos, M.D. Senior Research Physician Clinical Pharmacology Unit Institut Jules Bordet Background Amplification of HER2 occurs in approximately 20%
Recent advances in the management of metastatic breast cancer in older adults
Recent advances in the management of metastatic breast cancer in older adults Laura Biganzoli Medical Oncology Dept New Hospital of Prato Istituto Toscano Tumori Italy Important recent advances in the
DEBATE: NUEVOS TRATAMIENTOS EN CÁNCER DE MAMA POSICIONAMIENTO Y ALGORITMO TERAPÉUTICO CÁNCER DE MAMA HER 2 POSITIVO
DEBATE: NUEVOS TRATAMIENTOS EN CÁNCER DE MAMA POSICIONAMIENTO Y ALGORITMO TERAPÉUTICO CÁNCER DE MAMA HER 2 POSITIVO DEBATE: NUEVOS TRATAMIENTOS EN CÁNCER DE MAMA POSICIONAMIENTO Y ALGORITMO TERAPÉUTICO
Systemic therapy: HER-2 update. Hans Wildiers Multidisciplinair Borst Centrum/Algemene medische oncologie UZ Leuven
Systemic therapy: HER-2 update Hans Wildiers Multidisciplinair Borst Centrum/Algemene medische oncologie UZ Leuven New drugs Strategic issues Specific anti-her2 drugs Lapa$nib /Nera$nib Baselga & Swain,
Translational Breast Cancer Research Consortium (TBCRC) 022
Phase II trial of Neratinib and Capecitabine for Patients with Human Epidermal Growth Factor Receptor 2- Positive (HER2+) Breast Cancer Brain Metastases Translational Breast Cancer Research Consortium
Advanced HER2+ Breast Cancer: New Options and How to Deploy Them. José Baselga MD, PhD
Advanced HER2 Breast Cancer: New Options and How to Deploy Them José Baselga MD, PhD HER2 signaling results in a multitude of cellular effects, including increased cellular proliferation HER2 HER3 RAS
Targeted/Immunotherapy & Molecular Profiling State-of-the-art in Cancer Care
Targeted/Immunotherapy & Molecular Profiling State-of-the-art in Cancer Care Manmeet Ahluwalia, MD, FACP Miller Family Endowed Chair in Neuro-Oncology Director Brain Metastasis Research Program Cleveland
A vision for HER2 future
School of Medical Oncology Department of Medical and Biological Sciences - University of Udine Department of Oncology - University Hospital of Udine A vision for HER2 future Current therapeutic algorithm
The next wave of successful drug therapy strategies in HER2-positive breast cancer. Hans Wildiers University Hospitals Leuven Belgium
The next wave of successful drug therapy strategies in HER2-positive breast cancer Hans Wildiers University Hospitals Leuven Belgium Trastuzumab in 1st Line significantly improved the prognosis of HER2-positive
PROSTATA MULTIDISCIPLINARITA IN URO-ONCOLOGIA INTEGRAZIONE TERAPIA SISTEMICA-TRATTAMENTO LOCALE. Dr.ssa Ori Ishiwa Dr Sergio Bracarda
15 anno di fondazione del GUONE MULTIDISCIPLINARITA IN URO-ONCOLOGIA Aviano, 10 settembre 2010 INTEGRAZIONE TERAPIA SISTEMICA-TRATTAMENTO LOCALE PROSTATA Dr.ssa Ori Ishiwa Dr Sergio Bracarda UOC Oncologia
Immunoconjugates in Both the Adjuvant and Metastatic Setting
Immunoconjugates in Both the Adjuvant and Metastatic Setting Mark Pegram, M.D. Director, Stanford Breast Oncology Program Co-Director, Molecular Therapeutics Program Trastuzumab Treatment of Breast Tumor
Present and emerging treatment options in Her-2/neu overexpressing metastatic breast cancer
Present and emerging treatment options in Her-2/neu overexpressing metastatic breast cancer Christoph C. Zielinski Clinical Division of Oncology, Department of Medicine I and Comprehensive Cancer Center,
Dieta Brandsma, Department of Neuro-oncology, Netherlands Cancer Institute, Amsterdam, The Netherlands
What is hot in breast cancer brain metastases? Dieta Brandsma, Department of Neuro-oncology, Netherlands Cancer Institute, Amsterdam, The Netherlands 8th Annual Brain Metastases Research and Emerging Therapy
Targe:ng HER2 in Metasta:c Breast Cancer in 2014
Targe:ng HER2 in Metasta:c Breast Cancer in 2014 Kimberly L. Blackwell MD Professor Department of Medicine and Radia:on Oncology Duke University Medical Center Director, Breast Cancer Program Duke Cancer
Enfermedad con sobreexpresión de HER-2 neu
Enfermedad con sobreexpresión de HER-2 neu Elsa Dalmau Parc Taulí Sabadell. Hospital Universitari. Enfermedad con sobreexpresión de HER-2 neu ÍNDICE Neoadyuvancia Adyuvancia Enfermedad avanzada Enfermedad
Optimal treatment of brain metastases in breast cancer : Are we there yet?
Optimal treatment of brain metastases in breast cancer : Are we there yet? Hamdy A. Azim MSc,MD Oncology Department, School Of Medicine Cairo University Question # 1 : What do we need to know about Brain
Il trattamento medico
III Sessione: La malattia in fase avanzata Il trattamento medico Emilio Bria Oncologia, Dipartimento di Medicina, Università di Verona, Azienda Ospedaliera Universitaria Integrata Verona emilio.bria@univr.it
Optimal Management of Isolated HER2+ve Brain Metastases
Optimal Management of Isolated HER2+ve Brain Metastases Eliot Sims November 2013 Background Her2+ve patients 15% of all breast cancer Even with adjuvant trastuzumab 10-15% relapse Trastuzumab does not
OVERVIEW DAGLI STUDI CLINICI CON NAB-PACLITAXEL Studio GAP. Alberto Zaniboni. Oncologia Medica, Fondazione Poliambulanza Brescia
OVERVIEW DAGLI STUDI CLINICI CON NAB-PACLITAXEL Studio GAP Alberto Zaniboni Oncologia Medica, Fondazione Poliambulanza Brescia A Phase II randomized trial comparing a combination of Abraxane and Gemcitabine
Le nuove tossicità in oncologia: come cambia l informazione al paziente
Ospedale Sacro Cuore- Don Calabria U.O.C. Oncologia - Cancer Care Center Negrar (VR) Le nuove tossicità in oncologia: come cambia l informazione al paziente Cosa dice il medico, cosa sente il paziente
Nivolumab: esperienze italiane nel carcinoma polmonare avanzato
NSCLC avanzato: quali novità nel 2018? Negrar, 30 Ottobre 2018 Nivolumab: esperienze italiane nel carcinoma polmonare avanzato Francesco Grossi UOC Oncologia Medica Fondazione IRCCS Ca Granda Ospedale
Systemic therapy for HER2+ Advanced Breast Cancer
Systemic therapy for HER2+ Advanced Breast Cancer F. Cardoso, MD Director, Breast Unit, Champalimaud Clinical Center, Lisbon, Portugal ESMO Board of Directors & NR Committee Chair ESO Breast Cancer Program
Inibitori delle chinasi ciclino dipendenti nel trattamento della malattia metastatica HR-positiva Gli studi clinici
Inibitori delle chinasi ciclino dipendenti nel trattamento della malattia metastatica HR-positiva Gli studi clinici Laura Orlando UOC Oncologia & Breast Unit Brindisi Verona 22/04/2016 Summary Studi con
Karcinom dojke. PANEL: Semir Bešlija, Zdenka Gojković, Robert Šeparović, Tajana Silovski
Karcinom dojke PANEL: Semir Bešlija, Zdenka Gojković, Robert Šeparović, Tajana Silovski MBC: HER2 PHEREXA: Study Design Multicenter, randomized, open-label phase III trial Stratified by prior CNS disease,
Metastasi viscerali: altre opzioni oltre la chemioterapia. Ormonoterapia e Agentianti-Her2. - Valentina Sini -
Metastasi viscerali: altre opzioni oltre la chemioterapia. Ormonoterapia e Agentianti-Her2 - Valentina Sini - Metastatic Breast Cancer ER- Her2-20% ER- Her2+ ER+ Her2+ 5% 15% ER+ Her2- ER+ Her2+ ER- Her2+
Biobanking of Breast Cancer: Ultimately leading to prevention of brain metastases
Biobanking of Breast Cancer: Ultimately leading to prevention of brain metastases A.Hoeben, MD PhD Medical Oncologist Content. Introduction: -> need to optimize current treatment options for brain metastasized
Nuovo paradigma terapeutico nel trattamento del carcinoma mammario HER2+ metastatico: dagli studi alla pratica clinica Prima linea di trattamento
Nuovo paradigma terapeutico nel trattamento del carcinoma mammario HER2+ metastatico: dagli studi alla pratica clinica Prima linea di trattamento Prof. Sabino De Placido Dip. di Endocrinologia ed Oncologia
Overview: Immunotherapy in CNS Metastases
Overview: Immunotherapy in CNS Metastases Manmeet Ahluwalia, MD, FACP Miller Family Endowed Chair in Neuro-Oncology Director Brain Metastasis Research Program Cleveland Clinic Disclosures Consultant- Monteris
Brain metastases and meningitis carcinomatosa: Prof. Rafal Dziadziuszko Medical University of Gdańsk, Poland
Brain metastases and meningitis carcinomatosa: a palliative situation? Prof. Rafal Dziadziuszko Medical University of Gdańsk, Poland SAMO, Lucerne, February 1-2, 2013 Treatment options for NSCLC patients
Brain metastases: future developments. Emilie Le Rhun Lille, France
Brain metastases: future developments Emilie Le Rhun Lille, France Disclosures ELR has received research grants from Mundipharma and Amgen and honoraria for lectures or advisory board participation from
ONT-380 and HER2+ Breast Cancer
ONT-380 and HER2+ Breast Cancer Diana F. Hausman, MD CMO, VP Clinical Development Oncothyreon Inc. PNW Bio February 10 2015 Copyright 2014 Copyright Oncothyreon 2014 Oncothyreon Oncothyreon Leading Oncology
Recent Update in Management of Breast Cancer: Medical Oncology. Jin Hee Ahn, M.D., PhD. 23-April-2015
2015 GBCC & 4 th IBCS 1/37 Recent Update in Management of Breast Cancer: Medical Oncology Jin Hee Ahn, M.D., PhD. 23-April-2015 Department of Oncology, Asan Medical Center, UUCM, Seoul, Korea 2/37 3/37
Contemporary Chemotherapy-Based Strategies for First-Line Metastatic Breast Cancer
Contemporary Chemotherapy-Based Strategies for First-Line Metastatic Breast Cancer Hope S. Rugo, MD Professor of Medicine Director, Breast Oncology and Clinical Trials Education University of California
New Targeted Agents Demonstrate Greater Efficacy and Tolerability in the Treatment of HER2-positive Breast Cancer
New Evidence reports on presentations given at ASCO 2012 New Targeted Agents Demonstrate Greater Efficacy and Tolerability in the Treatment of HER2-positive Breast Cancer Presentations at ASCO 2012 Breast
Systemic Therapy of HER2-positive Breast Cancer
Systemic Therapy of HER2-positive Breast Cancer Tanja Cufer, MD, PhD University Clinic Golnik, Medical Faculty Ljubljana, Slovenia ESO ESMO Masterclass, Belgrade 2017 Relative Risk HER2-positive Breast
Systemic Therapy of HER2-positive Breast Cancer
Systemic Therapy of HER2-positive Breast Cancer Tanja Cufer, MD, PhD University Clinic Golnik, Medical Faculty Ljubljana, Slovenia ESO ESMO Masterclass, Belgrade 2018 HER2-positive Breast Cancer Adjuvant
Cáncer de mama HER2+/RE+ vs HER2+/RE : Una misma enfermedad? Dra E. Ciruelos Departamento de Oncología Médica Hospital Universitario 12 de Octubre
Cáncer de mama HER2+/RE+ vs HER2+/RE : Una misma enfermedad? Dra E. Ciruelos Departamento de Oncología Médica Hospital Universitario 12 de Octubre Recurrence of HER2-positive breast cancer (A) Time to
William J. Gradishar MD
Northwestern University Feinberg School of Medicine Management of HER2+ MBC SOBO 2012 William J. Gradishar MD Betsy Bramsen Professor of Breast Oncology Director, Maggie Daley Center for Women s Cancer
Carcinoma della Mammella Novità in tema di Adiuvante
Convegno Nazionale AIOM Giovani, Perugia 8-9 Luglio 2016 Carcinoma della Mammella Novità in tema di Adiuvante Antonella Palazzo, MD, PhD Istituto Europeo Oncologico di Milano The goal in Early Breast Cancer
Managing Breast Cancer Brain Metastases Carey K. Anders, MD November 2014
Managing Breast Cancer Brain Metastases Carey K. Anders, MD November 2014 Brief Overview Challenges faced Subtype predilection and prognosis Local therapy Focused radiation Radiosensitizers Systemic approaches
非臨床試験 臨床の立場から 京都大学医学部附属病院戸井雅和
資料 2 2 非臨床試験 臨床の立場から 京都大学医学部附属病院戸井雅和 1 Preclinical studies Therapeutic Window: Efficacy/Toxicity Disease Specificity Subtype Specificity Combination: Concurrent/Sequential Therapeutic situation: Response/
Focus sulla malattia metastatica ormonosensibile (mhspc) ADT e Terapia ormonale: quando e a chi?
Focus sulla malattia metastatica ormonosensibile (mhspc) ADT e Terapia ormonale: quando e a chi? Paolo Andrea Zucali Dipartimento di Oncologia HUMANITAS CANCER CENTER Rozzano - Milano AGENDA Literature
La sequenza terapeutica nel paziente con NSCLC avanzato in base all istologia e alla caratterizzazione molecolare: Impatto sulla pratica clinica?
La sequenza terapeutica nel paziente con NSCLC avanzato in base all istologia e alla caratterizzazione molecolare: Impatto sulla pratica clinica? GRUPPO A Luca Toschi (former Vanesa Gregorc) Who are oncogene
Evidenze cliniche nel trattamento del RCC
Criteri di scelta nel trattamento sistemico del carcinoma renale Evidenze cliniche nel trattamento del RCC Alessandro Morabito Unità Sperimentazioni Cliniche Istituto Nazionale Tumori di Napoli Napoli,
Resistance to anti-her2 therapies. Service d Oncologie Médicale
Resistance to anti-her2 therapies Pr David Khayat Service d Oncologie Médicale Groupe Hospitalier Pitié Salpêtrière -Paris Disclosure statment Trastuzumab in HER2+ MBC A major impact but resistance will
La via del segnale PI3K/AKT/mTOR Inibitori di mtor nel carcinoma mammario
La via del segnale PI3K/AKT/mTOR Inibitori di mtor nel carcinoma mammario Alessandra Modena U.O.C. Oncologia Medica Direttore: Dott.ssa Stefania Gori Ospedale Sacro Cuore - Don Calabria 29 novembre 2016
Advances in Breast Cancer Therapeutics in the Adjuvant and Metastatic Settings. Eve Rodler, MD University of California at Davis October 2016
Advances in Breast Cancer Therapeutics in the Adjuvant and Metastatic Settings Eve Rodler, MD University of California at Davis October 2016 17th Annual Advances in Oncology September 30-October 1, 2016
Management of Brain Metastases Sanjiv S. Agarwala, MD
Management of Brain Metastases Sanjiv S. Agarwala, MD Professor of Medicine Temple University School of Medicine Chief, Oncology & Hematology St. Luke s Cancer Center, Bethlehem, PA, USA Incidence (US):
Emerging Agents in HER2-positive Disease. Mary Cianfrocca, DO Director, Breast Oncology Program Banner MD Anderson Cancer Center Gilbert, AZ
Emerging Agents in HER2-positive Disease Mary Cianfrocca, DO Director, Breast Oncology Program Banner MD Anderson Cancer Center Gilbert, AZ Signal Transduction by the HER Family and Potential Mechanisms
Keywords Breast cancer Brain metastasis Lapatinib Capecitabine. Introduction
Int Canc Conf J (2013) 2:9 13 DOI 10.1007/s13691-012-0054-x CASE REPORT HER2-positive recurrent breast cancer and metastases of breast cancer, including life-threatening metastases to the brain and dura
SYSTEMIC THERAPY FOR HER-2+ ABC
SYSTEMIC THERAPY FOR HER-2+ ABC F. Cardoso, MD Director, Breast Unit, Champalimaud Clinical Center, Lisbon, Portugal ESO Breast Cancer Program Coordinator ESMO Board of Directors & NR Committee Chair EORTC
Update HER2. Rupert Bartsch. Department of Medicine 1, Clinical Division of Oncology Comprehensive Cancer Center Vienna Medical University of Vienna
Update HER2 Rupert Bartsch Department of Medicine 1, Clinical Division of Oncology Comprehensive Cancer Center Vienna Medical University of Vienna HER2: A Unique Story of Success Analysis of outcome in
Improving outcomes for NSCLC patients with brain metastases
Improving outcomes for NSCLC patients with brain metastases Martin Schuler West German Cancer Center, Essen, Germany In Switzerland, afatinib is approved as monotherapy for patients with non-small cell
HER2-positive Breast Cancer
HER2-positive Breast Cancer Multiple choices what to use when? Thomas Ruhstaller Brustzentrum St. Gallen Adjuvant setting NCIC MA5 N Engl J Med 06, 2103 6 x CEF can 6 x CMF oral HER2 + pg schlecht in allen
Surgery for recurrent brain metastases
Surgery for recurrent brain metastases Pr Philippe METELLUS Neurosurgeon, Clairval Hospital Center, Marseille 8th Annual Brain Metastases Research and Emerging Therapy Conference September 21st, 2018 Conflict
PIK3CA Mutations in HER2-Positive Breast Cancer
2016.4.29. GBCC PIK3CA Mutations in HER2-Positive Breast Cancer Seock-Ah Im, MD, PhD. Department of Internal Medicine Seoul National University Hospital Contents Introduction TCGA data HER2 signaling pathway
L interpretazione delle curve di sopravvivenza negli studi clinici: le domande del clinico
L interpretazione delle curve di sopravvivenza negli studi clinici: le domande del clinico Stefania Gori U.O.C. Oncologia Medica Cancer Care Center Sacro Cuore-Don Calabria Negrar- VERONA Presidente eletto
Biomarkers for HER2-directed Therapies : Past Failures and Future Perspectives
Biomarkers for HER2-directed Therapies : Past Failures and Future Perspectives Ian Krop Dana-Farber Cancer Institute Harvard Medical School Inchon 2018 Adjuvant Trastuzumab Improves Outcomes in HER2+ Breast
L Oncologo Sperimentatore nel Disegno e nella Conduzione dello Studio Clinico
L Oncologo Sperimentatore nel Disegno e nella Conduzione dello Studio Clinico Antonino Musolino U.O.C. Oncologia Medica Azienda Ospedaliero-Universitaria di Parma LA SETTIMANA DEL GOIRC Negrar, 29 Aprile
LA MALATTIA METASTATICA. La malattia HR positiva/her2 negativa: quale terapia di I linea? Come scegliere? Jennifer Foglietta P.O.
LA MALATTIA METASTATICA La malattia HR positiva/her2 negativa: quale terapia di I linea? Come scegliere? Jennifer Foglietta P.O. Narni-Amelia (TR) Outline Re-testing metastatic disease Chemo- vs endocrine-therapy
Virtual Journal Club: Front-Line Therapy and Beyond Recent Perspectives on ALK-Positive Non-Small Cell Lung Cancer.
Virtual Journal Club: Front-Line Therapy and Beyond Recent Perspectives on ALK-Positive Non-Small Cell Lung Cancer Reference Slides ALK Rearrangement in NSCLC ALK (anaplastic lymphoma kinase) is a receptor
Breast Cancer Immunotherapy. Leisha A. Emens, MD PhD Johns Hopkins University Bloomberg Kimmel Institute for Cancer Immunotherapy
Breast Cancer Immunotherapy Leisha A. Emens, MD PhD Johns Hopkins University Bloomberg Kimmel Institute for Cancer Immunotherapy Conflict of Interest I have the following financial relationships to disclose:
mcrpc 2014 TRA EVOLUZIONE E RIVOLUZIONE: COME ORIENTARSI NEL LABIRINTO DELLE TERAPIE
mcrpc 2014 TRA EVOLUZIONE E RIVOLUZIONE: COME ORIENTARSI NEL LABIRINTO DELLE TERAPIE IL CARCINOMA PROSTATICO, UNA MALATTIA ETEROGENEA? RAZIONALE E RISULTATI DEL TRATTAMENTO CHEMIOTERAPICO ASSOCIATO ALL
ASCO and San Antonio Updates
ASCO and San Antonio Updates 30 th Annual Miami Breast Cancer Conference March 7-10, 2013 Debu Tripathy, MD Professor of Medicine University of Southern California Norris Comprehensive Cancer Center Breakthroughs
Management Guidelines and Targeted Therapies in Metastatic Non-Small Cell Lung Cancer: An Oncologist s Perspective
Management Guidelines and Targeted Therapies in Metastatic Non-Small Cell Lung Cancer: An Oncologist s Perspective Julie R. Brahmer, M.D. Associate Professor of Oncology The Sidney Kimmel Comprehensive
Van Cutsem E et al. Proc ASCO 2009;Abstract LBA4509.
Efficacy Results from the ToGA Trial: A Phase III Study of Trastuzumab Added to Standard Chemotherapy in First-Line HER2- Positive Advanced Gastric Cancer Van Cutsem E et al. Proc ASCO 2009;Abstract LBA4509.
NeoadjuvantTreatment In BC When, How, Who?
NeoadjuvantTreatment In BC When, How, Who? Clifford Hudis, M.D. Chief, Breast Cancer Medicine Service, MSKCC Professor of Medicine, Weill Cornell Medical College President, ASCO 15 Potential Benefits Of
Breast cancer update. Iryna Kuchuk, MD Oncology department Meir Medical Center
Breast cancer update Iryna Kuchuk, MD Oncology department Meir Medical Center Overview Cancer Death Rates* Among Women, US,1930-2009 Factors Associated with Reduction In Breast Cancer Mortality Early
Alleinige Radiochirurgie und alleinige Systemtherapie zwei «extreme» Entwicklungen in der Behandlung von Hirnmetastasen?
Department of Radiation Oncology Chairman: Prof. Dr. Matthias Guckenberger Alleinige Radiochirurgie und alleinige Systemtherapie zwei «extreme» Entwicklungen in der Behandlung von Hirnmetastasen? Matthias
Metastatic Breast Cancer What is new? Subtypes and variation?
Metastatic Breast Cancer What is new? Subtypes and variation? Anne Blaes, MD, MS University of Minnesota, Division of Hematology/Oncology Director, Adult Cancer Survivor Program Current estimates for metastatic
Breast cancer treatment
Report from the San Antonio Breast Cancer Symposium Breast cancer treatment Determining the best options for select patient groups Sara Soldera, MD, Resident; Nathaniel Bouganim, MD, FRCPC, Medical Oncologist;
Lo studio BOLERO-1 Quali potranno essere le future ricadute nella pratica clinica? Antonella Ferro UO Oncologia Medica Trento
Lo studio BOLERO-1 Quali potranno essere le future ricadute nella pratica clinica? Antonella Ferro UO Oncologia Medica Trento TRASTUZUMAB most important breakthrough in the management of BC Trastuzumab
Targeted Agents as Maintenance Therapy. Karen Kelly, MD Professor of Medicine UC Davis Cancer Center
Targeted Agents as Maintenance Therapy Karen Kelly, MD Professor of Medicine UC Davis Cancer Center Disclosures Genentech Advisory Board Maintenance Therapy Defined Treatment Non-Progressing Patients Drug
Intensive follow up after primary. PRO: Pierfranco Conte
Intensive follow up after primary curative therapy PRO: Pierfranco Conte Follow up : Guidelines Mammography PE BSE Intensive Follow-up BMD (DEXA) Gynecologic examination AIOM 1 (2012) yearly Q 3/6 m for
New chemotherapy drugs in metastatic breast cancer. Guy Jerusalem, MD, PhD
New chemotherapy drugs in metastatic breast cancer Guy Jerusalem, MD, PhD MBC Patients survival over time Median survival increases over time, but is still measured in months This is not yet a chronic
NSCLC: Terapia medica nella fase avanzata. Paolo Bidoli S.C. Oncologia Medica H S. Gerardo Monza
NSCLC: Terapia medica nella fase avanzata Paolo Bidoli S.C. Oncologia Medica H S. Gerardo Monza First-line Second-line Third-line Not approved CT AND SILENT APPROVAL Docetaxel 1999 Paclitaxel Gemcitabine
Predicting outcome in metastatic breast cancer
Predicting outcome in metastatic breast cancer Aleix Prat, MD, PhD Medical Oncology Department Translational Genomics and Targeted Therapeutics in Solid Tumors Monday, 15 th January, Manchester, UK Disclosures
Novel Chemotherapy Agents for Metastatic Breast Cancer. Joanne L. Blum, MD, PhD Baylor-Sammons Cancer Center Dallas, TX
Novel Chemotherapy Agents for Metastatic Breast Cancer Joanne L. Blum, MD, PhD Baylor-Sammons Cancer Center Dallas, TX New Chemotherapy Agents in Breast Cancer New classes of drugs Epothilones Halichondrin
Francesco Massari Oncologia Medica Azienda Ospedaliero Universitaria di Bologna Policlinico S. Orsola-Malpighi
Focus sulla malattia metastatica ormonosensibile (mhspc) ADT e Chemioterapia: quando e a chi? Francesco Massari Oncologia Medica Azienda Ospedaliero Universitaria di Bologna Policlinico S. Orsola-Malpighi
Novel Preoperative Therapies for HER2-Positive Breast Cancer. Debu Tripathy, MD University of Southern California Norris Comprehensive Cancer Center
Novel Preoperative Therapies for HER2-Positive Breast Cancer Debu Tripathy, MD University of Southern California Norris Comprehensive Cancer Center Key Findings to Date in the Neoadjuvant Therapy of HER2+
Systemic Therapy Considerations in Inflammatory Breast Cancer
Systemic Therapy Considerations in Inflammatory Breast Cancer Shani Paluch-Shimon, MBBS, MSc Director, Breast Oncology Unit Shaare Zedek Medical Centre, Jerusalem Israel Disclosures Roche: Speakers bureau,
Il paziente anziano con malattia oncologica avanzata: il tumore del colon-retto
Milano 05.10.2018 Il paziente anziano con malattia oncologica avanzata: il tumore del colon-retto Salvatore Corallo U.O.C. Oncologia Medica IRCCS Istituto Nazionale dei Tumori Milano CRC in elderly patients
Advances in the Management of Metastatic Her 2 Positive Breast Cancer
Advances in the Management of Metastatic Her 2 Positive Breast Cancer Sunil Verma MD, MSEd, FRCPC Medical Oncologist Research Lead, Division of Medical Oncology Chair, Breast Medical Oncology Sunnybrook
DR LUIS MANSO UNIDAD TUMORES DE MAMA Y GINECOLÓGICOS HOSPITAL 12 DE OCTUBRE MADRID
DR LUIS MANSO UNIDAD TUMORES DE MAMA Y GINECOLÓGICOS HOSPITAL 12 DE OCTUBRE MADRID RESUMEN DE ARTICULOS THERESA BOLERO 3 NOAH UP-DATE GEPAR SIXTO RADIOTHERAPY EBCTCG CTCs MISCELANEAS Lancet Oncol 2014;